Scientific Reports · 2018 · 35 citations · 41 references
Life SciencesMolecular BiologyOncologyCancer GeneticsMolecular OncologySignal TransductionCancer Cell SignalingCancer GenomicsNoncoding Rna BiologyNoncoding Rna FunctionNoncoding Rna In CancerRna-protein InteractionsCancer-related Noncoding Rna FunctionLong Noncoding Rna RegulationLong Noncoding Rna-mediated ResistanceMapk Pathway MutationsMapk SignalingMicrorna Function In CancerMicrorna-mediated Pathway RegulationNras Mutation
Despite major advances in targeted melanoma therapies, drug resistance limits their efficacy. Long noncoding RNAs (lncRNAs) are transcriptome elements that do not encode proteins but are important regulatory molecules. LncRNAs have been implicated in cancer development and response to different therapeutics and are thus potential treatment targets; however, the majority of their functions and molecular interactions remain unexplored. In this study, we identify a novel cytoplasmic intergenic lincRNA (MIRAT), which is upregulated following prolonged MAPK inhibition in NRAS mutant melanoma and modulates MAPK signaling by binding to the MEK scaffold protein IQGAP1. Collectively, our results present MIRAT's direct modulatory effect on the MAPK pathway and highlight the relevance of cytoplasmic lncRNAs as potential targets in drug resistant cancer.
41
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman, Axel Hauschild, Caroline Robert et al. · New England Journal of Medicine · 2011 · 7.7K citations · Full text
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian, Hubing Shi, Qi Wang et al. · Nature · 2010 · 2.2K citations
Medicine, Cancer Biology, Oncology +11
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty, Caroline Robert, Peter Hersey et al. · New England Journal of Medicine · 2012 · 2.1K citations · Full text
Medicine, Oncology, Pharmacology +17